Study questions accuracy of genetic test for opioid use disorder

Opioid misuse and specifically opioid use disorder (OUD), continues to represent a significant U.S. public health threat, with more than 6 million Americans aged 12 and older meeting the criteria for OUD in 2022.

Notable shakeups this week; Recursion’s mixed data; Eli Lilly’s $1B bet; and more

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 8, 2024

FDA to make decision about Karuna’s schizophrenia drug by next September

The FDA is set to decide whether to approve Karuna Therapeutics’ schizophrenia drug by Sept. 26, the Boston biotech said Wednesday before the markets opened.

November 30, 2023

Pharmalittle: We’re reading about fake studies, AbbVie investing in psychedelics, and more

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more

May 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.